Research Topics
| Francis P WordenSummaryAffiliation: University of Michigan Country: USA Publications
| Collaborators
|
Detail Information
Publications
Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasionFrancis P Worden
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, USA
Laryngoscope 119:1510-7. 2009..Patients were treated with chemoradiation after a >50% primary tumor response to one cycle of neoadjuvant chemotherapy (IC). We analyzed outcomes for T4 patients with cartilage invasion from both studies...- Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy numberFrancis P Worden
Department of Internal Medicine, Division of Hematology Oncology, University of Michigan, Ann Arbor, MI, USA
J Clin Oncol 26:3138-46. 2008..To test induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CRT) or surgery/radiotherapy (RT) for advanced oropharyngeal cancer and to assess the effect of human papilloma virus (HPV) on response and outcome... 
Controversies in the management of oropharynx cancerFrancis P Worden
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
J Natl Compr Canc Netw 6:707-14. 2008..Unfortunately, these and other questions concerning the management of locally advanced oropharyngeal cancers are outstanding. Hence, it is critical that eligible patients are screened for and encouraged to participate in clinical trials...- A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007Francis P Worden
Department of Internal Medicine, Division of Medical Oncology, University of Michigan, Ann Arbor, Michigan 48109 0848, USA
Cancer 107:319-27. 2006..To validate these results and to determine the feasibility of this combination, a Phase II study was conducted by the Southwest Oncology Group (SWOG S0007)... 
Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancerBryan J Schneider
Department of Internal Medicine, Weill Cornell Medical College, New York, NY, USA
Clin Lung Cancer 11:223-7. 2010..This trial was designed to evaluate irinotecan/cisplatin plus maintenance imatinib in patients with c-Kit-positive disease (the transmembrane receptor c-Kit is the product of the c-KIT protooncogene)...- EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancerBhavna Kumar
Department of Otolaryngology Head and Neck Surgery, University of Michigan Comprehensive Cancer Center Head and Neck Cancer Program, Ann Arbor, MI 48109, USA
J Clin Oncol 26:3128-37. 2008..To prospectively identify markers of response to therapy and outcome in an organ-sparing trial for advanced oropharyngeal cancer... - Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional resultsFelix Y Feng
Department of Radiation Oncology, University of Michigan, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA
J Clin Oncol 28:2732-8. 2010..To assess clinical and functional results of chemoradiotherapy for oropharyngeal cancer (OPC), utilizing intensity-modulated radiotherapy (IMRT) to spare the important swallowing structures to reduce post-therapy dysphagia... - Chemotherapy alone for organ preservation in advanced laryngeal cancerVasu Divi
Department of Otolaryngology Head and Neck Surgery, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA
Head Neck 32:1040-7. 2010.... - Predictive factors of local-regional recurrences following parotid sparing intensity modulated or 3D conformal radiotherapy for head and neck cancerMary Feng
Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA
Radiother Oncol 77:32-8. 2005..These factors may aid in the selection of patients for studies of treatment intensification using IMRT... - Metabolic abnormalities associated with weight loss during chemoirradiation of head-and-neck cancerAlexander Lin
Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109-0010, USA
Int J Radiat Oncol Biol Phys 63:1413-8. 2005..These intensive measures should be enacted before a 10% weight loss is reached... - Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smokingBhavna Kumar
Department of Otolaryngology Head and Neck Surgery, University of Michigan, Ann Arbor, MI, USA
Int J Radiat Oncol Biol Phys 69:S109-11. 2007..Smoking cessation and strategies to target EGFR may be useful adjuncts for therapy to improve outcome in the cases with the poorest biomarker profile... - Acceleration of hyperfractionated chemoradiation regimen for advanced head and neck cancerAaron M Allen
Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA
Head Neck 29:137-42. 2007..Our aim was to evaluate the acceleration of a hyperfractionated, concurrent chemoradiation regimen (HxCRT) for advanced head and neck squamous cell carcinoma (HNSCC)... - HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North AmericansJessica H Maxwell
University of Michigan Medical School, The University of Michigan Health System and Comprehensive Cancer Center, Ann Arbor, MI, USA
Head Neck 32:562-7. 2010..The HPV, p16, and EBV status was examined in current University of Michigan patients with NPC... - Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrenceJessica H Maxwell
Departments of Otolaryngology Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA
Clin Cancer Res 16:1226-35. 2010.... - Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancerJoshua A Bauer
Department of Pharmacology, University of Michigan, Ann Arbor, MI, USA
Int J Radiat Oncol Biol Phys 69:S106-8. 2007..Cisplatin resistance remains a barrier to organ-sparing and survival of patients with advanced head and neck squamous cell carcinoma (HNSCC). Targeted therapies to overcome cisplatin-resistant HNSCC are being developed... - Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcomaRashmi Chugh
Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Medical School, Ann Arbor, Michigan, USA
Cancer 109:2315-22. 2007..The pharmacokinetics of ifosfamide and CYP3A measurements observed are reported... - Diagnostic modalities for distant metastasis in head and neck squamous cell carcinoma: are we changing life expectancy?Matthew E Spector
Department of Otolaryngology Head and Neck Surgery, University of Michigan Health System, Ann Arbor, Michigan, USA
Laryngoscope 122:1507-11. 2012..To determine if the various imaging modalities for distant metastasis (DM) diagnosis alters life expectancy in head and neck squamous cell carcinoma (HNSCC)... - High SEPT9_v1 Expression Is Associated with Poor Clinical Outcomes in Head and Neck Squamous Cell CarcinomaLaura Stanbery
The Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
Transl Oncol 3:239-45. 2010..00094). SEPT9_v1 is highly expressed in HNSCC, and a high expression of SEPT9_v1 is associated with poor clinical outcomes. These data indicate that SEPT9_v1 warrants additional investigation as a potential biomarker for HNSCC... - Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparingAvraham Eisbruch
Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109 0010, USA
Int J Radiat Oncol Biol Phys 59:28-42. 2004..Locoregional (LR) failures near the base of the skull, and their relationships to the targets in the high neck, were examined in a series of patients who underwent intensity-modulated radiotherapy (IMRT) for head-and-neck cancer... - Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapyBryan J Schneider
Department of Internal Medicine, Division of Hematology Oncology, University of Michigan, Ann Arbor, Michigan, USA
J Thorac Oncol 3:1454-9. 2008..To evaluate the efficacy and toxicity of the combination of celecoxib and docetaxel in patients with advanced non-small cell lung cancer after failure of platinum-based therapy... - Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancerBryan J Schneider
Division of Hematology Oncology, Department of Internal Medicine, Weill Cornell Medical College, 525 East 68th Street, J 321, New York, NY 10021, USA
Invest New Drugs 27:571-8. 2009.... - Matted nodes: poor prognostic marker in oropharyngeal squamous cell carcinoma independent of HPV and EGFR statusMatthew E Spector
Departments of Otolaryngology Head and Neck Surgery, University of Michigan Health System, Ann Arbor, Michigan, USA
Head Neck 34:1727-33. 2012..Despite better prognosis, there is a group of oropharyngeal squamous cell carcinoma (SCC) human papillomavirus (HPV)+ patients who experience treatment failure and succumb to distant metastasis... - Osteocutaneous free tissue transplantation for mandibular osteoradionecrosisShamir P Chandarana
Department of Otolaryngology Head and Neck Surgery, University of Michigan Health System, Ann Arbor, Michigan 48109 0312, USA
J Reconstr Microsurg 29:5-14. 2013..To describe the success rate, complications, and functional outcomes of patients who are treated with osteocutaneous free tissue transplantation for grade 4 mandibular osteoradionecrosis (ORN)... - Mebendazole monotherapy and long-term disease control in metastatic adrenocortical carcinomaIrina Y Dobrosotskaya
Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
Endocr Pract 17:e59-62. 2011..To describe successful long-term tumor control in metastatic adrenocortical carcinoma, a relatively rare tumor with limited treatment options outside of surgery... - Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcomaFrancis P Worden
Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
J Clin Oncol 23:105-12. 2005..These results suggest that HD ifosfamide combination regimens should not be used as first-line therapy for patients with STS... - A phase II study of imatinib in patients with advanced anaplastic thyroid cancerHuan T Ha
Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
Thyroid 20:975-80. 2010..Imatinib inhibits tyrosine kinase activity of Bcr-ABL and PDGF. We hypothesize that patients with ATC that over-expresses PDGF receptors or cABL will respond to imatinib... - Use of warfarin in the patient with cancerJoanna Maudlin Pangilinan
University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109, USA
J Support Oncol 5:131-6. 2007 - Sinonasal undifferentiated carcinoma: a 13-year experience at a single institutionErin M Lin
Department of Otolaryngology Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan
Skull Base 20:61-7. 2010..It is possible that up-front radiation or chemoradiation will lead to better local control rates, though surgery remains a mainstay of treatment. In all cases, the cervical nodes should be addressed with primary treatment... - Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinomaGavin C Mackie
Department of Radiological Sciences, St. Jude Children's Research Hospital, 332 North Lauderdale, Mail Stop 752, Memphis, Tennessee 38105-2794, USA
J Clin Endocrinol Metab 91:2665-71. 2006..CONCLUSIONS: Most adrenocortical carcinomas accumulate and retain FDG and thus can be visualized by PET. However, false-negative findings are possible, especially with very small lesions... - Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II studyEzra E W Cohen
Section of Hematology Oncology, Department of Medicine, University of Chicago Division of Biological Sciences, 5801 S Ellis, Chicago, IL 60637, USA
J Clin Oncol 26:4708-13. 2008..This multi-institutional study assessed the activity and safety of axitinib, an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 in patients with advanced thyroid cancer...